Boehringer gets into guided-missile drugs with $1 5 billion deal for NBE reuters.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from reuters.com Daily Mail and Mail on Sunday newspapers.
John Miller
2 分钟阅读
ZURICH, Dec 10 (Reuters) - Boehringer Ingelheim is paying 1.18 billion euros ($1.5 billion) for Swiss-based NBE Therapeutics, the German drugmaker said on Thursday, adding pipeline candidates including a drug in early trials against triple-negative breast cancer and lung cancer.
Basel-based biotech NBE, in which Boehringer’s venture fund previously had a stake along with Denmark’s Novo Nordisk Foundation and Prague-based PPF Group, is hoping to develop so-called Antibody-drug Conjugates (ADCs) from its own platform against a series of cancers.
ADCs combine a monoclonal antibody with a chemical drug payload, aiming to pack a one-two punch against cancers and potentially other diseases.
Boehringer Ingelheim is paying 1.18 billion euros for Swiss-based NBE Therapeutics, the German drugmaker said on Thursday, adding pipeline candidates including a drug in early trials against.
By John Miller ZURICH (Reuters) - Boehringer Ingelheim is paying 1.18 billion euros ($1.5 billion) for Swiss-based NBE Therapeutics, the German drugma.